CHA
TEVA icon

Carmichael Hill & Associates’s Teva Pharmaceuticals TEVA Stock Holding History

Carmichael Hill & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,550
Closed -$11.7K – 806
2023
Q2 		$11.7K Hold
1,550
– – 0.01% 544
2023
Q1 		$13.7K Hold
1,550
– – 0.01% 504
2022
Q4 		$14.1K Sell
1,550
-675
-30% -$5.89K 0.01% 505
2022
Q3 		$18K Hold
2,225
– – 0.01% 500
2022
Q2 		$17K Hold
2,225
– – 0.01% 497
2022
Q1 		$21K Hold
2,225
– – 0.01% 493
2021
Q4 		$18K Hold
2,225
– – 0.01% 538
2021
Q3 		$22K Buy
2,225
+675
+44% +$6.32K 0.01% 503
2021
Q2 		$15K Hold
1,550
– – 0.01% 551
2021
Q1 		$18K Hold
1,550
– – 0.01% 513
2020
Q4 		$15K Hold
1,550
– – 0.01% 518
2020
Q3 		$14K Hold
1,550
– – 0.01% 483
2020
Q2 		$19K Hold
1,550
– – 0.01% 424
2020
Q1 		$14K Hold
1,550
– – 0.01% 417
2019
Q4 		$15K Buy
+1,550
New +$13.8K 0.01% 433

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Carmichael Hill & Associates's TEVA Position: Q3 2023 in Review

Carmichael Hill & Associates sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 1,550 shares — an estimated $11.7K sold.

Carmichael Hill & Associates first reported a position in TEVA in Q4 2019 and held it in 15 quarters. The position peaked at $22K in Q3 2021. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • Carmichael Hill & Associates reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Carmichael Hill & Associates sold 1,550 Teva Pharmaceuticals shares in Q3 2023, an estimated $11.7K.
  • Carmichael Hill & Associates first reported a position in Teva Pharmaceuticals in Q4 2019 and held it in 15 quarters.
  • Carmichael Hill & Associates's Teva Pharmaceuticals position peaked at $22K in Q3 2021.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Carmichael Hill & Associates's 13F filing for Q3 2023, filed 30 Oct 2023.